Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALPN NYSE:IBIO NASDAQ:IMNM NASDAQ:NXTC NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shs2 shsIBIOiBio$0.87+0.2%$0.76$0.56▼$6.89$17.14M0.861.45 million shs94,604 shsIMNMImmunome$9.87+0.2%$9.99$5.15▼$15.51$859.22M1.921.02 million shs324,224 shsNXTCNextCure$5.63-0.5%$5.13$2.69▼$19.20$15.08M1.2749,499 shs927 shsVTGNVistaGen Therapeutics$3.02-0.7%$3.03$1.90▼$3.88$92.35M0.55267,483 shs152,693 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%IBIOiBio+3.22%-9.67%+18.71%+12.84%-51.12%IMNMImmunome+9.57%+1.76%-1.70%+12.57%-36.45%NXTCNextCure+0.52%+2.56%+9.61%-1.08%-66.79%VTGNVistaGen Therapeutics+4.83%-13.14%-4.10%+52.00%+1.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$64.97$64.81$8.33▼$65.00$4.46B0.971.92 million shs2 shsIBIOiBio$0.87+0.2%$0.76$0.56▼$6.89$17.14M0.861.45 million shs94,604 shsIMNMImmunome$9.87+0.2%$9.99$5.15▼$15.51$859.22M1.921.02 million shs324,224 shsNXTCNextCure$5.63-0.5%$5.13$2.69▼$19.20$15.08M1.2749,499 shs927 shsVTGNVistaGen Therapeutics$3.02-0.7%$3.03$1.90▼$3.88$92.35M0.55267,483 shs152,693 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences0.00%0.00%0.00%0.00%0.00%IBIOiBio+3.22%-9.67%+18.71%+12.84%-51.12%IMNMImmunome+9.57%+1.76%-1.70%+12.57%-36.45%NXTCNextCure+0.52%+2.56%+9.61%-1.08%-66.79%VTGNVistaGen Therapeutics+4.83%-13.14%-4.10%+52.00%+1.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00473.39% UpsideIMNMImmunome 3.00Buy$22.89131.90% UpsideNXTCNextCure 2.67Moderate Buy$25.50352.61% UpsideVTGNVistaGen Therapeutics 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest VTGN, NXTC, ALPN, IBIO, and IMNM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$21.009/5/2025IMNMImmunomeCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/25/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/22/2025IMNMImmunomeEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$18.008/7/2025IMNMImmunomeJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$23.00 ➝ $22.008/7/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$21.007/15/2025NXTCNextCurePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$36.00 ➝ $15.007/8/2025NXTCNextCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.006/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$56.52M78.85N/AN/A$4.85 per share13.40IBIOiBio$400K42.85N/AN/A$1.41 per share0.62IMNMImmunome$12.59M68.24N/AN/A$2.27 per share4.35NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/AVTGNVistaGen Therapeutics$646K143.43N/AN/A$2.44 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-65.17%-14.86%-11.82%N/AIBIOiBio-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/AIMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)VTGNVistaGen Therapeutics-$51.42M-$1.78N/AN/AN/A-6,777.08%-74.06%-64.10%11/6/2025 (Estimated)Latest VTGN, NXTC, ALPN, IBIO, and IMNM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/A8/7/2025Q1 2026VTGNVistaGen Therapeutics-$0.47-$0.47N/A-$0.47$0.22 million$0.24 million8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A9.569.56IBIOiBio0.051.761.76IMNMImmunomeN/A12.1312.13NXTCNextCureN/A3.713.71VTGNVistaGen TherapeuticsN/A5.985.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%IBIOiBio7.90%IMNMImmunome44.58%NXTCNextCure42.65%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%IBIOiBio0.58%IMNMImmunome7.69%NXTCNextCure17.90%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences14268.60 million39.58 millionOptionableIBIOiBio10019.66 million9.82 millionN/AIMNMImmunome4087.05 million80.35 millionOptionableNXTCNextCure902.68 million2.20 millionOptionableVTGNVistaGen Therapeutics4030.68 million29.81 millionOptionableVTGN, NXTC, ALPN, IBIO, and IMNM HeadlinesRecent News About These CompaniesVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Significant Growth in Short InterestSeptember 16 at 8:37 AM | marketbeat.comVistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy SummitSeptember 9, 2025 | businesswire.comVistaGen Therapeutics, Inc. $VTGN Shares Bought by ADAR1 Capital Management LLCSeptember 4, 2025 | marketbeat.comVistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety TrialSeptember 2, 2025 | sg.finance.yahoo.comWhile institutions invested in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) benefited from last week's 11% gain, retail investors stood to gain the mostAugust 17, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | msn.comVistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ...August 8, 2025 | finance.yahoo.comVistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comQ1 2026 Vistagen Therapeutics Inc Earnings Call TranscriptAugust 8, 2025 | gurufocus.comVistagen (VTGN) Q1 R&D Expense Jumps 54%August 7, 2025 | fool.comVistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue EstimatesAugust 7, 2025 | zacks.comVistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate UpdateAugust 7, 2025 | businesswire.comVistaGen Therapeutics Q1 2026 Earnings PreviewAugust 6, 2025 | msn.comVistagen to Present at the BTIG Virtual Biotechnology ConferenceJuly 24, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comVistagen Honored for Outstanding Workplace Culture and Mental Health LeadershipJuly 15, 2025 | businesswire.comStifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 DelayJuly 3, 2025 | msn.comVTGN Vistagen Therapeutics, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comVistagen Appoints Elissa Cote as Chief Corporate Development OfficerJune 25, 2025 | businesswire.comVistagen Therapeutics, Inc. (VTGN) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call TranscriptJune 22, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTGN, NXTC, ALPN, IBIO, and IMNM Company DescriptionsAlpine Immune Sciences NASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.iBio NYSE:IBIO$0.87 +0.00 (+0.23%) As of 11:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Immunome NASDAQ:IMNM$9.87 +0.02 (+0.20%) As of 11:20 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.NextCure NASDAQ:NXTC$5.63 -0.03 (-0.46%) As of 11:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.VistaGen Therapeutics NASDAQ:VTGN$3.02 -0.02 (-0.66%) As of 11:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
